|
|
|
| Effect of glutathione combined with adenosylmethionine butadiesulfonic acid in the treatment of intrahepatic cholestasis of pregnancy |
| PAN Juerong1 MENG Wenxia2 YE Yunfei1 |
1.Department of Obstetrics and Gynecology, Liuzhou General Hospital, Guangxi Zhuang Autonomous Region, Liuzhou 545006, China;
2.Department of Obstetric Critical, Liuzhou General Hospital, Guangxi Zhuang Autonomous Region, Liuzhou 545006, China |
|
|
|
Abstract Objective To study the effect of glutathione combined with adenosylmethionine butadiesulfonic acid (ABC) in the treatment of intrahepatic cholestasis of pregnancy (ICP). Methods From February 2016 to February 2018, in Liuzhou General Hospital, 80 patients with ICP were selected, they were divided into study group (40 cases) and control group (40 cases) according to the random number table method. The control group was treated with ursodeoxycholic acid, the study group was treated with glutathione combined with ABC. The clinical efficacy and the change of liver function index [aspartate aminotransferase (AST), bile acid (TBA), alanine transaminase (ALT)] and serum interleukin-18 (IL-18), tumor necrosis factor-α (TNF-α) were analyzed, and adverse pregnancy outcome of the two groups before and after treatment was recorded. Results The total effective rate of the study group was higher than the control group (P < 0.05). The levels of AST, TBA and ALT in the two groups were lower than before the treatment (P < 0.05), and the study group was lower than the control group (P < 0.05). The serum levels of IL-18 and TNF-α in the two groups were lower than those before treatment (P < 0.05), and the study group was lower than the control group (P < 0.05). The incidence of amniotic fluid contamination and fetal distress in the study group were lower than those in the control group (P < 0.05). Conclusion Glutathione combined with ABC in the treatment of ICP has a significant effect，it is helpful to reducing liver function damage, and reducing the incidence of adverse pregnancy outcome. It is worthy of clinical application.
|
|
|
|
|
|
[1] Liu J，Murray AM，Mankus EB，et al. adjuvant use of rifampin for refractory intrahepatic cholestasis of pregnancy [J]. Obstet Gynecol，2018，132（3）：678-681.
[2] 董明珍，张琳.妊娠期肝内胆汁淤积症对妊娠结局的影响[J].临床和实验医学杂志，2013，12（19）：1578-1578.
[3] 朱名超，朱娅，韩利蓉，等.血清甘胆酸、总胆汁酸、丙氨酸转氨酶及促甲状腺激素水平测定在妊娠期肝内胆汁淤积症诊断中的应用价值[J].中华妇幼临床医学杂志：电子版，2016，12（6）：651-654.
[4] 李蕾，赵新颜，欧晓娟，等.妊娠期肝内胆汁淤积症的临床分析[J].中华肝脏病杂志，2013，21（4）：295-298.
[5] 任丽平，徐军，胡峥，等.多烯磷脂酰胆碱联合茵栀黄和谷胱甘肽治疗妊娠期肝内胆汁淤积症的研究[J].临床和实验医学杂志，2016，15（10）：999-1001.
[6] 蔡燕红.丁二磺酸腺苷蛋氨酸对妊娠期肝内胆汁淤积症患者胆汁酸、肝酶指标及妊娠期结局的影响[J].河北医药，2017，39（8）：1155-1157.
[7] 王海燕，哈丽亚·哈力木别克.熊去氧胆酸与丁二磺酸腺苷蛋氨酸联合治疗乙型肝炎合并妊娠期肝内胆汁淤积症的效果观察[J].中国现代医生，2018，56（4）：16-19.
[8] 徐晖，黄夏冰，伍涛，等.妊娠期肝内胆汁淤积症患者相关生化指标的检测及临床意义[J].中华全科医学，2017， 15（7）：1192-1193.
[9] 曹杰，蔡艾杞，田立碧，等.熊去氧胆酸、腺苷蛋氨酸联合多烯磷脂酰胆碱对妊娠期肝内胆汁淤积症患者相关指标的影响[J].中国药房，2017，28（18）：2509-2511.
[10] Han F，Xu L，Huang Y，et al. Magnesium sulphate can alleviate oxidative stress and reduce inflammatory cytokines in rat placenta of intrahepatic cholestasis of pregnancy model [J]. Arch Gynecol Obstet，2018，298（3）：631-638.
[11] 俞颖，周承亮，俞田田，等.滋养细胞的内质网应激在妊娠期肝内胆汁淤积症中的作用[J].中华妇产科杂志，2017，52（6）：392-397.
[12] 热依汗古丽·买买提，刘海燕，韩文晖，等.妊娠期肝内胆汁淤积症对早产发生率的影响[J].中华流行病学杂志，2017，38（10）：1415-1418.
[13] 庄小平.丁二磺酸腺苷蛋氨酸肠溶片对妊娠期肝内胆汁淤积症重症患者瘙痒程度、妊娠结局及肝功能的影响[J].肝脏，2017，22（3）：229-231.
[14] 谢萍，王莹，尹燕平，等.S-腺苷甲硫氨酸联合还原型谷胱甘肽治疗妊娠期肝内胆汁淤积症[J].国际妇产科学杂志，2017，44（2）：222-224.
[15] 范怡冰，殷彩华.妊娠期肝内胆汁淤积症孕妇血清生化指标改变与妊娠结局预测[J].中国妇幼健康研究，2015， 26（6）：1225-1227.
[16] 谢鑫，黄晓平，曹晓辉，等.谷胱甘肽联合熊去氧胆酸治疗妊娠期肝内胆汁淤积症的效果及对围产结局的影响[J].江苏医药，2018，44（4）：444-446.
[17] 董晶晶.丁二磺酸腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症疗效评价[J].中国药业，2018，27（9）：41-43.
[18] 周学梅.还原型谷胱甘肽治疗妊娠期肝内胆汁淤积症的效果观察[J].中国妇幼保健，2017，32（9）：1885-1887.
[19] 张丽明，李素玉，王延安，等.胆瘀方结合熊去氧胆酸片及丁二磺酸腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症的临床分析[J].空军医学杂志，2018，34（1）：65-68.
[20] 卢文芳，梁燕.妊娠期肝内胆汁淤积症患者的妊娠结局分析[J].当代医学，2017，23（35）：153-155.
[21] 李桂香，刘玲玲，毛玉芳，等.丁二磺酸腺苷蛋氨酸联合地塞米松对妊娠期肝内胆汁淤积症患者肝功能及血清TNF-α，IL-12水平的影响[J].现代生物医学进展，2017，17（19）：3765-3768.
[22] 吴秋静，刘婕.熊去氧胆酸联合腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症患者的临床效果观察[J].中外医学研究，2018，16(26):149-151.
[23] 张建梅，洪博，徐硕，等.熊去氧胆酸联合S-腺苷蛋氨酸改善妊娠期肝内胆汁淤积症临床疗效及对患者血清中磷脂转运蛋白、白细胞介素1表达水平的影响[J].中国临床医生杂志，2016，44（9）：87-89. |
|
|
|
